Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
MedSIR
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06676917 | https://clinicaltrials.gov/study/NCT06048718
Assets
Linked programs
- Datopotamab deruxtecan: Registry Stop Signal (4/5)
- Trastuzumab-Deruxtecan (T-DXd): Watchlist Signal (2/5)